Study of U3-1402 in subjects with non-small cell lung cancer

2024-511205-33-00 Protocol U31402-A-U102 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 18 May 2020 · Status Ongoing, recruitment ended · 2 EU/EEA countries · 9 sites · Protocol U31402-A-U102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 310
Countries 2
Sites 9

METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 May 2020 → ongoing
Decision date (initial)
2024-08-15
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511205-33-00
EudraCT number
2017-000543-41
ClinicalTrials.gov
NCT03260491

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

VersionLevelCodeTermSystem organ class
20.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Fortrea Inc.

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
Fortrea Inc.

Locations

2 EU/EEA countries · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruitment ended 8 1
Spain Ongoing, recruitment ended 20 8
Rest of world
Japan, United States, Taiwan, Korea, Democratic People's Republic of
282

Investigational sites

Netherlands

1 site · Ongoing, recruitment ended
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Pneumology, Plesmanlaan 121, 1066 CX, Amsterdam

Spain

8 sites · Ongoing, recruitment ended
Hospital Universitario Ramon Y Cajal
-, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Clinica Universidad De Navarra
-, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitari Vall D Hebron
-, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Hm Sanchinarro
-, Calle Ona 10, 28050, Madrid
Hospital Universitario Quironsalud Madrid
-, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital General Universitario Gregorio Maranon
-, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Quironsalud Barcelona
-, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario 12 De Octubre
-, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2020-05-19 2020-07-07 2025-04-15
Spain 2020-05-18 2020-06-26 2025-12-01

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-25 Netherlands Acceptable with conditions
2024-08-15
2024-08-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-15 Netherlands Acceptable
2025-02-03
2025-02-05
3 SUBSTANTIAL MODIFICATION SM-2 2025-06-18 Acceptable 2025-09-01
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-09-10 Netherlands Acceptable 2025-09-10
5 SUBSTANTIAL MODIFICATION SM-3 2026-01-21 Netherlands Acceptable
2026-04-14
2026-04-14